Skip to main content
Premium Trial:

Request an Annual Quote

Protagen, Bayer Schering Evaluate UNIarray Technology

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German protein analysis and diagnostics firm Protagen and Bayer Schering Pharma today announced the closing of a cooperation contract for the discovery of biomarkers for endometriosis.

Terms of the deal were not disclosed.

The goal of the collaboration between the two firms is to evaluate the ability of Protagen's UNIarray technology to discover autoantibody patterns for the predictive diagnosis of endometriosis, which affects about 5 percent to 10 percent of women worldwide, Protagen said in a statement.

The current gold standard of diagnosis for the disease is laparoscopy, but "proteomic profiling of inflammation, angiogenesis, and tissue remodeling processes are becoming increasingly important to understand the biology of endometriosis," Protagen said.